SEARCH

Current Edition

Alzheimer

Biogen CEO to step down as company pulls back from Alzheimer’s drug

Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s …

Continue Reading →
Aduhelm

Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

Biogen’s drug for Alzheimer’s disease, once considered a blockbuster-in-waiting, has run into so many obstacles since gaining approval last June that the company is now …

Continue Reading →
Aduhelm

Biogen pulls European application for Aduhelm in another setback for the Alzheimer’s drug

Dive Brief: Biogen has withdrawn a request to start selling its Alzheimer’s disease drug in Europe, marking the latest setback in the company’s efforts to …

Continue Reading →
Alzheimer

Medicare finalizes policy limiting coverage of Biogen Alzheimer’s drug

Medicare will not pay for Biogen’s new Alzheimer’s medicine unless prospective patients are enrolled in a clinical trial, the U.S. government said Thursday in a …

Continue Reading →
Acadia

FDA panel to review once-rejected Acadia drug for psychosis

Dive Brief: After receiving a rejection last year, Acadia said Wednesday that the Food and Drug Administration agreed to review its resubmitted application to expand …

Continue Reading →
Alzheimer

Biogen, struggling to sell Alzheimer’s drug, begins layoffs to save money

Biogen has begun to lay off employees as part of a previously disclosed effort to lower annual expenses by half a billion dollars. The move comes …

Continue Reading →
Aduhelm

Roche, nearing major trial readouts, starts new Alzheimer’s drug study

Dive Brief: Roche is expanding clinical testing of its experimental Alzheimer’s disease drug gantenerumab, announcing Thursday the start of a late-stage trial in people with …

Continue Reading →
Al Sandrock

Al Sandrock, former top Biogen scientist, to join drug discovery startup’s board

Dive Brief: Al Sandrock, a former top Biogen executive who led development of the company’s Alzheimer’s drug Aduhelm, is joining the board of directors at …

Continue Reading →
Alzheimer

Biogen’s Alzheimer’s drug sales remain slow as company warns of further cost cuts

Biogen recorded $1 million in revenue from its new treatment for Alzheimer’s disease in the last quarter of 2021, offering the latest evidence that the …

Continue Reading →
Alzheimer

Lilly slows FDA submission of Alzheimer’s drug after Medicare decision

Dive Brief: Eli Lilly is pushing back the timing for when it expects to finish submitting an application for U.S. approval of its experimental drug …

Continue Reading →
Alzheimer

Cortexyme to shift focus after FDA places hold on experimental Alzheimer’s drug

Dive Brief: The Food and Drug Administration has ordered California biotech Cortexyme to stop testing of an experimental Alzheimer’s disease drug, notifying the drugmaker in …

Continue Reading →
Alzheimer

Medicare proposes to limit coverage of Biogen Alzheimer’s drug

Medicare will restrict coverage of Biogen’s controversial Alzheimer’s treatment only to patients who take part in a rigorous clinical trial, the federal government announced Tuesday, …

Continue Reading →
Alzheimer

Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird’s crucial year

The biggest industry news of the week came not from the J.P. Morgan Healthcare Conference or any associated announcements, but from Washington, D.C, where the …

Continue Reading →
Alzheimer

Pfizer’s big bet on mRNA, Biogen ‘proven wrong’ on Aduhelm price and the next cell therapies

Biotechnology stocks ended the first day of the J.P. Morgan Healthcare Conference in the green, but only barely. By Monday afternoon, a closely followed index of …

Continue Reading →
Aduhelm

Biogen reserves four years for trial meant to confirm its Alzheimer’s drug works

A crucial study evaluating Biogen’s approved drug for Alzheimer’s disease is set to begin in May, the company disclosed Thursday, and if enrollment goes as …

Continue Reading →
Alzheimer

GSK sets sights on brain diseases through Oxford partnership

Diseases of the brain and central nervous system have been notoriously challenging to treat, even for the world’s largest and most well-resourced drug companies. But …

Continue Reading →
Aduhelm

Biogen seeking more information in investigation of Aduhelm patient’s death

Aduhelm has come under intense scrutiny since the Food and Drug Administration’s controversial June approval of the drug, the first new Alzheimer’s treatment in decades …

Continue Reading →
Aduhelm

Anticipating Aduhelm’s costs, Medicare plans big jump in premiums

The decision affects Medicare Part B, which pays for health care services typically received outside of institutional settings like hospitals and nursing homes. The planned …

Continue Reading →
Alzheimer

Cortexyme plans path forward for Alzheimer’s drug that failed study

Faced with the failure of a key clinical trial, a California-based biotech is pressing ahead with plans to test its experimental Alzheimer’s drug in another …

Continue Reading →
Aduhelm

With approval plans underway, Lilly’s next move is to test its Alzheimer’s drug against Biogen’s

With few treatment options and millions of patients in the U.S. alone, Alzheimer’s has long been one of the biggest targets for drug developers. Yet, …

Continue Reading →